

## Targeting TGF- $\beta$ pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19

Vuong Trieu<sup>1</sup>, Saran Saund<sup>1</sup>, Prashant V. Rahate<sup>2</sup>, Viljay B. Barge<sup>3</sup>, K. Sunil Nalk<sup>4</sup>  
Hitesh Windlass<sup>5</sup>, Fatih M. Uckun<sup>6</sup>

<sup>1</sup>Oncotelic Inc., Agoura Hills, CA 91301, USA.

<sup>2</sup>Seven Star Hospital, Nagpur-440009, Maharashtra, India.

<sup>3</sup>Government Medical College and Chhatrapati Pramila Raje Hospital, Chowk, Kolhapur-431001, Maharashtra, India.

<sup>4</sup>Government Medical College and Government General Hospital, Srikakulam-532001, Andhra Pradesh, India.

<sup>5</sup>Windlas Biotech Pvt. Ltd., Dehradun UR 248110, India

<sup>6</sup>Ares Pharmaceuticals, LLC, St. Paul, MN 55110, USA

\*Correspondence to: Fatih M. Uckun, MD, PhD, fatih.uckun@aresmit.com

### ABSTRACT

Our COVID-19 drug candidate ARTIVeda<sup>TM</sup>/PulmoHeal is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of TGF- $\beta$  targeting anti-malaria phytomedicine Artemisinin with documented anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety and efficacy of ARTIVeda<sup>TM</sup> in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase IV study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile, and the only ARTIVeda-related adverse events were transient mild rash and mild hypertension. Notably, ARTIVeda, when added to the SOC, accelerated the recovery of patients with mild-moderate COVID-19. While all patients were symptomatic at baseline (WHO score = 2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score = 1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (P=0.028, Fisher's exact test). This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score = 4) treated with SOC

alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (P=0.004, Log-rank test). These data provide clinical proof of concept that targeting the TGF- $\beta$  pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease.

## Introduction

Effective drugs are needed to prevent the potentially deadly complications of COVID-19 (1-3) and thereby reduce its fatality rate has become one of the main causes of death (4-9). Artemisinin is an anti-inflammatory phytomedicine with broad-spectrum antiviral activity and a commonly used anti-malaria drug (10-12). Artemisinin and some of its chemical derivatives exhibit broad-spectrum antiviral activity against pathogenic human viruses (11,12). Notably, recent docking studies indicated that Artemisinin and its derivative Artesunate could bind the SARS-CoV-2 spike protein in a way that would interfere with its docking onto the human ACE2 receptor protein, which is the required first step in the host infection process of the coronavirus disease 2019 (COVID-19) (13,14). Studies by Cao et al.(15) and Gilmore et al. confirmed the antiviral activity of Artemisinin and its derivatives against SARS-2-CoV-2 (16). Its documented anti-SARS-CoV-2 activity has been attributed to its ability to inhibit spike-protein mediated and TGF- $\beta$ -dependent early steps in the infection process (12). It is noteworthy that the incidence of COVID-19 and related deaths have been very low in countries with regular use of artemisinin-based anti-malaria drugs (17). Consequently, Artemisinin has recently been repurposed as a potential COVID-19 drug (12). Li et al. reported the results from an open-label non-randomized study in which 41 COVID-19 patients received either standard of care (SOC) therapy (control) or SOC combined with Artemisinin plus piperazine (AP) (18). Patients in the AP group showed a faster clearance of SARS-CoV-2 than control patients.

Our COVID-19 drug candidate ARTIVeda<sup>TM</sup> is a novel gelatin capsule formulation for oral delivery of Artemisinin. The purpose of the present study was to evaluate the safety and efficacy of ARTIVeda<sup>TM</sup> in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase IV study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile and significantly accelerated the recovery of patients with mild-moderate COVID-19 when added to the SOC. For patients with moderate COVID-19 (WHO Score = 4),

the median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (P=0.004, Log-rank test). These findings provide clinical proof of concept that the use of ARTIVeda as an adjunct to the SOC may result in faster recovery of patients with mild-moderate COVID-19.

## **Materials and Methods**

**ARTIVeda™/PulmoHeal, a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of Artemisinin.** The product, ArtiVeda™/PulmoHeal (License # UK.AY-401/2018, Ministry of AYUSH, India), is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of the active ingredient Artemisinin for treatment of COVID-19. This dual-function COVID-19 drug candidate has potent antiviral activity against SARS-CoV-2 and is expected to mitigate the TGF- $\beta$  mediated inflammatory injury associated with the cytokine storm and viral sepsis in critically ill COVID-19 patients.

**ARTI-19 Clinical Study.** The ARTI-19 is a randomized, open-label Phase IV study was designed to evaluate the safety and efficacy of ARTIVeda when used in combination with the standard of care (SOC) in mild-moderate COVID-19 patients in Bangalore, Karnataka, India. The official title of the study protocol is “A Prospective, Randomized, Multi-center, Open-label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19”. The ARTI-19 trial was cleared by Indian regulatory authorities and is registered under the Clinical Trials Registry India (CTRI) with three active sites (CTRI/2020/09/028044). This study is sponsored by Oncotelic, Inc. (USA) and Windlas Biotech Private Limited (India). The execution of the trial has been contracted to the Clinical Research Organization (CRO) Abiogenesis Clinpharm Private Limited (Hyderabad, India). The primary endpoint of the study is time to recovery from the signs and symptoms of COVID-19.

The study will initially enroll 120 adult patients with RT-PCR confirmed and symptomatic mild-moderate COVID-19 not requiring any oxygen therapy (i.e., scores of 2-4 on the 10-point WHO Clinical Progression Scale) who will be randomized to either standard of care (SOC) plus ARTIVeda or SOC alone. Consenting registered patients are randomly divided by computer-generated randomization sequence 2:1 into the experimental arm (Group 1: ARTIVeda plus SOC): control arm (Group 2: SOC alone). This report details the clinical data in the first 60

randomized patients who were treated at the following 3 sites: 1) Site 203: Government Medical College & Government General Hospital, Srikakulam, ANDHRA PRADESH; 2) Site 202: Rajarshi Chhatrapati Shahu Maharaj Government Medical College and Chhatrapati Pramila Raje Hospital, MAHARASHTRA; and 3) Site 201: Seven Star Hospital, MAHARASHTRA. The SOC was generally as described in the national clinical management protocol of India: "COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division)". There were site-to-site variations in choice of SOC drugs. Site 201 employed Remdesivir, prednisolone, low molecular weight heparin, and doxycycline as the key components of the SOC. Azithromycin, dexamethasone were part of the SOC used at Site 202. Site 203 SOC included Ivermectin, doxycycline, and inhaled steroids.

For patient eligibility in the trial, the Inclusion Criteria are 1. Confirmed case of COVID-19 infection by laboratory tests for COVID-19; 2. Age limit: 21 to 60 years of age male, or non-pregnant or non-lactating female; 3. Patients with oxygen saturation higher than 95% and without any requirement of oxygen therapy or assisted ventilation; 4. Patients willing to give their informed consent to participate in the clinical trial. Patients are excluded if they have one or more of the following Exclusion Criteria: 1. COVID-19 positive patients above 60 years of age or below 21 years; 2. Patients on Immuno-suppression therapy; 3. Patients with associated renal or hepatic impairment; 4. Pregnant women or lactating mothers; 5. Patients in an advanced stage of disease requiring emergency medical intervention like pneumonia, bronchial asthma, organ failure; 6. Patients whom ventilator support is required; 7. Patients not willing to give their informed consent to participate in the clinical trial; 8. Patients with the following co-morbidities: insulin-dependent diabetes, hypertension with cardiac symptoms, morbid obesity with diabetes and/or hypertension. Uncontrolled diabetes. Uncontrolled hypertension.

**Ethics Statement and Approval.** ARTI-19 is being performed in adherence to the Good Clinical Practice (GCP) guidelines, Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) guidelines, and Indian Council of Medical Research. The study was approved by Ethics Committees at the three participating institutions: 1) Government Medical College & Government General Hospital, Srikakulam, ANDHRA PRADESH. 2) Rajarshi Chhatrapati Shahu Maharaj Government Medical College and Chhatrapati Pramila Raje Hospital, MAHARASHTRA. And 3) Seven Star Hospital, MAHARASHTRA.

## Results

**Patient characteristics.** We present data from 60 Asian patients with COVID-19 who were treated on the ART-19 study between October 8, 2020 and November 21, 2020. The date for data cut off was November 5, 2020. 39 patients were randomized to the experimental arm and received ARTIVeda as an adjunct to SOC, whereas 21 patients were randomized to the control arm and received SOC without ARTIVeda. The baseline patient characteristics are shown in **Table 1**. The median age was 44.5 years (Range: 18-59 years). 38 patients (63.3%) were male and 22 patients (36.7%) were female. All 60 patients had RT-PCR confirmed symptomatic mild-moderate COVID-19 with a score of 2-4 on the 10-point WHO clinical progression scale not requiring any oxygen therapy, of whom 28 (46.7%) were hospitalized patients with a score of 4 (**Table 1**). There were no significant differences in the baseline characteristics of patients on the experimental versus control arms of the protocol.

**Safety.** As of the data cut-off date, safety data were available for all 60 participants, including 39 patients who received ARTIVeda. All AEs encountered in all 60 patients are shown in **Table 2** according to their SOC, severity, and relatedness to the assigned treatments. There were no incidences of drug-related deaths or discontinuation of therapy. No treatment-related  $\geq$ Grade 3 AEs were observed in any of the patients. The only ARTIVeda-related AEs were a single occurrence of transient mild rash and mild vertigo (**Table 2**). These AEs did not require additional treatment, and they did not cause discontinuation of the dosing or study. All AEs considered possibly or probably related to ARTIVeda have recovered/resolved with no sequelae. No laboratory abnormalities were observed in the SOC plus ARTIVeda group to suggest drug-related systemic or organ-specific toxicity. There were no clinically meaningful changes in laboratory values identified in observed values from baseline compared with the SOC alone group (**Table 3**). In particular, laboratory tests performed on day 28 showed: (a) no evidence of kidney toxicity, as documented by their normal serum BUN and creatinine levels; (b) no evidence of liver toxicity, as documented by their normal ALT, AST, and total bilirubin levels, and (b) no evidence of hematological toxicity, as documented by their normal and near-baseline RBC counts, hemoglobin, platelet counts, and WBC counts with normal percentages of neutrophils and lymphocytes.

**Efficacy.** More patients recovered faster when ARTIVeda was used as adjunct therapy alongside SOC. This was observed across all sites including Remdesivir-based SOC at site 201, Dexamethasone/Heparin-based SOC at site 202, and Ivermectin-based SOC at site 203. While all patients were symptomatic at baseline (WHO score = 2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score = 1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 ( $P=0.028$ , Fisher's exact test) (**Table 4**). These results indicate that ARTIVeda when added to the SOC accelerates the recovery of patients with mild-moderate COVID-19. This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score = 4) treated with SOC alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group ( $N=18$ ) but 14 days for the SOC alone group ( $N=10$ ) ( $P=0.004$ , Log-rank test) (**Figure 1**). While 11 of 18 (61.1%) hospitalized patients treated with SOC plus ARTIVeda became asymptomatic by day 5, only 2 of 10 (20%) of hospitalized patients treated with SOC alone did ( $P=0.04$ , Fisher's exact test).

## DISCUSSION

*Artemisia* species contain bioactive substances with pleiotropic biological effects (10, 12). For example, *Artemisia annua* contains anti-inflammatory sesquiterpenoids, including Artemisinin (viz.: Artesunate). Artemisinin and its antimalarial properties were discovered by the Chinese scientist Tu Youyu, who became one of the laureates of the 2015 Nobel Prize in Physiology or Medicine for this discovery (12). Artemisinin and Artemisinin derivatives are generally well-tolerated, especially when used for a short treatment course (10, 12, 18-24). Except for the rare occurrence of hepatotoxicity and mild-moderate headache, nausea, vomiting, fatigue, and anorexia, Artemisinin was found to be clinically safe in healthy volunteers as well as malaria patients (10, 12, 18-24). In the present study, ARTIVeda was administered daily for 5 days as an adjunct to the Remdesivir-based SOC at Site 201, Dexamethasone/Heparin-based SOC at Site 202, or Ivermectin-based SOC at Site 203. No treatment-related  $\geq$ Grade 3 AEs were observed in any of the patients. The only ARTIVeda-related AEs were mild rash and mild hypertension, and these AEs did not require additional treatment, and they did not cause discontinuation of the dosing or study. All AEs considered possibly or probably related to

ARTIVeda have recovered/resolved with no sequelae. No laboratory abnormalities were observed in the SOC plus ARTIVeda group to suggest drug-related systemic or organ-specific toxicity. Most importantly, no hepatotoxicity was observed in any of the 39 patients treated with ARTIVeda.

Artemisinin and some of its chemical derivatives exhibit broad-spectrum antiviral activity against pathogenic human viruses, including SARS-CoV-2 (11, 12). Artemisinin has also been shown to inhibit the expression of TGF- $\beta$  mRNA and protein both in vitro and in vivo (25-27). Artemisinin treatments mitigated the contribution of upregulated TGF- $\beta$  expression to the disease pathophysiology in rodent models of diabetic nephropathy as well as lupus nephritis (26, 27). High-risk COVID-19 patients have a higher probability of developing a potentially life-threatening multi-system inflammation caused by a cytokine release syndrome (CRS) (4-9). TGF- $\beta$  is one of the important pro-inflammatory cytokines that contribute to the inflammatory injury of lungs in COVID-19 patients during the CRS (28-31). Notably, infection with SARS-CoV increases the expression of TGF- $\beta$  and potentiates the TGF- $\beta$ -regulated MAPK-mediated inflammatory signals (32-35). The upregulation of TGF- $\beta$  genes in COVID-19 patients has also been documented (31). TGF- $\beta$  also worsens the severity of pulmonary edema and acute respiratory distress syndrome (ARDS) that develops after CRS by increasing capillary permeability and impairing alveolar fluid transportation in the lungs (36-40). In addition, neutrophil extracellular traps (NETs) that are formed via activation of the complement system and production of complement cleavage products during sepsis trigger TGF- $\beta$  release from platelets and thereby contribute to persistence of systemic inflammation and serious coagulopathy (41-45). Due to the pivotal role of TGF- $\beta$  in the pathophysiology of lung fibrosis that develops after inflammatory injury to the lungs (46-49), the use of a TGF- $\beta$  inhibitor like Artemisinin has the clinical potential to prevent pulmonary fibrosis in COVID-19 patients. Our results presented herein provide clinical proof of concept that targeting the TGF- $\beta$  pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease.

Artemisinin and some of its derivatives are being evaluated as COVID-19 therapeutics (12). ArtemiC is a medical spray containing Artemisinin, curcumin, Frankincense resin from the *Boswellia sacra* tree, and Vitamin C. In the controlled Phase II trial NCT04382040, patients with COVID-19 received ArtemiC spray in addition to standard care and preliminary data suggested

that ArtemiC may be more active than placebo in contributing to the improvement of the patients' condition (50). Likewise, the efficacy signal for the Artemisinin derivative Artesunate during a recently completed prospective, controlled clinical COVID-19 study was promising. In Artesunate treatment group, time to significant improvement of the symptoms, time to conversion to the negativity of SARS-CoV-2 tests, and length of hospital stay was shorter than in the control group (51). Additional data sets are expected from several ongoing active clinical trials designed to evaluate the efficacy of Artemisinin and its derivatives in COVID-19 patients, including NCT04387240 Phase 2 trial testing the efficacy of Artesunate and Artemisinin will be examined in patients with mild COVID-19, NCT04502342 trial testing the efficacy of cospherunate, a combination of Artesunate and amodiaquine, NCT04475107 Phase 2/3 trial testing the efficacy of pyramax, a combination of pyronaridine and Artesunate, IRCT20200607047682N1 Phase 2/3 trial testing the efficacy of Anval S (an oral syrup containing Artemisinin) plus Azithromycin, NCT04553705 trial testing the efficacy of Artemisinin combined with Omega-3 supplementation and thymoquinone, NCT04374019 Phase 2 trial testing the efficacy of Artemisia annua as well as Artesunate in high-risk COVID-19 patients.

In summary, Artemisinin-containing drugs, such as ARTIVeda, have clinical impact potential in the treatment of COVID-19 because it can prevent the progression of the disease and accelerate the recovery of patients before they develop potentially life-threatening complications. This dual-function COVID-19 drug candidate is hoped to mitigate the TGF- $\beta$  mediated inflammatory injury associated with the cytokine storm and viral sepsis in critically ill COVID-19 patients. Our study provides the rationale for further clinical development of ARTIVeda as a COVID-19 drug candidate. Based on the encouraging activity signal in mild-moderate COVID-19 patients, we are planning to start the clinical testing of ARTIVeda in severe to critically ill COVID-19 patients as well.

**Author contributions.** Each author has made significant and substantive contributions to the study, reviewed and revised the manuscript, provided final approval for submission of the final version. No medical writer was involved. V.T and F.M.U conceived the study, designed the evaluations reported in this paper, directed the data compilation and analysis, analyzed the data, and prepared the initial draft of the manuscript. Each author had access to the source data used in the analyses.



**Funding/Support.** This study was funded by Oncotelic, Inc., a wholly-owned subsidiary of Mateon Therapeutics.

**Conflict of Interest Statement.** Authors Vuong Trieu and Saran Saund were employed by the company Oncotelic, Inc., the sponsor for the clinical development of ArtiVeda™. Autor Hitesh Windlass was employed by Windlas Biotech Pvt. Ltd. Author Fatih Uckun was employed by Ares Pharmaceuticals, LLC. Vuong Trieu and Fatih Uckun are shareholders of Mateon Therapeutics, the sponsor for the clinical development of ArtiVeda™. These financial relationships could be construed as a potential conflict of interest.

**Role of the Funder/Sponsor.** The sponsor did not participate in the collection of data. The authors who participated in the analysis and decision to submit the manuscript for publication are affiliated with the sponsor.

## References

1. Woolf SH, Chapman DA, Lee JH. COVID-19 as the Leading Cause of Death in the United States. *JAMA*. Published online December 17, 2020. doi:10.1001/jama.2020.24865
2. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L, Taylor DDH. Excess deaths from COVID-19 and other causes, March-July 2020. *JAMA*. 2020;324(15):1562-1564. doi:10.1001/jama.2020.19545
3. Faust JS, Krumholz HM, Du C, et al. All-Cause Excess Mortality and COVID-19–Related Mortality Among US Adults Aged 25-44 Years, March-July 2020. *JAMA*. Published online December 16, 2020. doi:10.1001/jama.2020.24243
4. Uckun FM. Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation. *Front. Pharmacol.* 2020; 11:796. doi: 10.3389/fphar.2020.00796
5. Wu C, Chen X, Cai Y et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Internal Med.* 2020; Published Online: March 13, 2020. doi:10.1001/jamainternmed.2020.0994
6. Zhou F, Du R, Fan G et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054-62. [https://doi.org/10.1016/S0140.6736\(20\)30566.3](https://doi.org/10.1016/S0140.6736(20)30566.3)

7. Zheng Z, Peng F, Xu B et al. Risk factors of critical and mortal COVID-19 cases: A systematic literature review and meta-analysis. *Journal of Infection* 2020; S0163-4453(20)30234-6. doi: <https://doi.org/10.1016/j.jinf.2020.04.021>
8. Uckun FM. Prognostic Factors Associated with High-Risk for Fatal ARDS in COVID-19 and Potential Role for Precision Medicines as Part of COVID-19 Supportive Care Algorithms. *Ann Pulm Crit Care Med* 2020; 3(2):1-4
9. Uckun FM, Carlson J, Orhan C, Powell J, Pizzimenti NM, Van Wyk H, Ozercan IH, Volk M, Sahin K. Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure. *Front. Pharmacol.* 2020; 11:594321. doi: 10.3389/fphar.2020.594321
10. Li G, Li Y, Li Z, Zeng M. Chapter 6: Artemisinin and Derivatives: Clinical Studies. In Li G, Li Y, Li Z, Zeng M, eds. *Artemisinin-Based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them*. Academic Press; 2018:353-413.
11. D'alessandro, S, Scaccabarozzi D, Signorini L, Perego F, Ilboudo Dp, Ferrante P, Delbue S. The Use Of Antimalarial Drugs Against Viral Infection *Microorganisms* 2020; 8: 85, <https://doi.org/10.3390/Microorganisms8010085>
12. Uckun FM, Saund S, Windlass H, Trieu V. [Minireview] Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug. *Frontiers in Pharmacology*, 2021; submitted
13. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 2020; 367: 1444-1448. <https://doi.org/10.1126/science.abb2762>
14. Sehalia M, Chemat S. In-silico Studies of Antimalarial-agent Artemisinin and Derivatives Portray More Potent Binding to Lys353 and Lys31-Binding Hotspots of SARS-CoV-2 Spike Protein than Hydroxychloroquine: Potential Repurposing of Artemimol for COVID-19. *ChemRxiv*. 2020. Preprint. <https://doi.org/10.26434/chemrxiv.12098652.v1>.
15. Cao R, Hu H, Li Y, et al. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro. *ACS Infect Dis*. 2020;6(9):2524-2531.
16. Gilmore K, Zhou Y, Ramirez S, et al. In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2. *bioRxiv*. 2020. 10.05.326637; doi: <https://doi.org/10.1101/2020.10.05.326637>.
17. Kangbai JB, Babawo LS, Kaitibi D, Sandi AA, George AM, Sahr F. Re-reading ACT, BCG, and Low COVID-19 in Africa. *SN Comprehensive Clinical Medicine*. 2021 Jan:1-5. DOI: 10.1007/s42399-020-00704-3.

18. Li G, Yuan M, Li H, et al. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. *Int J Antimicrob Agents*. 2020;106216.
19. Duc DD, de Vries PJ, Nguyen XK, Le Nguyen B, Kager PA, van Boxtel CJ. The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. *Am J Trop Med Hyg*. 1994;51(6):785-790.
20. Ashton M, Gordi T, Trinh NH, et al. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. *Biopharm Drug Dispos*. 1998;19(4):245-250.
21. Hien TT, Hanpithakpong W, Truong NT, et al. Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. *Clin Ther*. 2011;33(5):644-654.
22. De Vries PJ, Tran KD, Nguyen XK, et al. The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. *Am J Trop Med Hyg*. 1997;56(5):503-507.
23. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. *Antimicrob Agents Chemother*. 2002;46(4):1026-1031.
24. Wang Q, Zou Y, Pan Z, et al. Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review. *Front Pharmacol*. 2020;11:562363.
25. Cao Y, Feng YH, Gao LW, et al. Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo. *Int Immunopharmacol*. 2019;70:110-116.
26. Zhang H, Qi S, Song Y, Ling C. Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF- $\beta$ 1 regulator and activating the Nrf2 signaling pathway. *Life Sci*. 2020;256:117966.
27. Wu X, Zhang W, Shi X, An P, Sun W, Wang Z. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. *Acta Biochim Biophys Sin (Shanghai)*. 2010;42(12):916-923.
28. Alhelfawi M. Potential approach for fighting against corona virus disease. *ASRJETS*. 2020;66:127-144.
29. Chen W. A potential treatment of COVID-19 with TGF- $\beta$  blockade. *International Journal of Biological Sciences*. 2020;16(11):1954-1955. Doi: 10.7150/ijbs.46891.
30. Uckun FM and Trieu VN. Medical-Scientific Rationale for a Randomized, Placebo-Controlled, Phase 2 Study of Trabedersen/OT-101 in COVID-19 Patients with Hypoxemic Respiratory Failure. *Annals Pulmonary and Critical Care Medicine* 2020; 3(1); 01-09.

31. Xiong Y, Liu Y, Cao L, Wang D, Guo, M, Jiang A, Guo D et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerging Microbes & Infections* 2020, 9:1, 761-770. doi: 10.1080/22221751.2020.1747363
32. He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, Deng Y, Yang L, Li J, Cai J, Qiu L, Wen K, Xu X, Jiang S. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. *J. Pathol.* 2006;210(3):288-297.
33. Zhao X, Nicholls JM, Chen YG. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signalling. *J. Biol. Chem.* 2008;283(6):3272-3280.
34. Wang CY, Lu CY, Li SW, Lai CC, Hua CH, Huang SH, Lin YJ, Hour MJ, Lin CW. SAR coronavirus papain-like protease up-regulates the collagen expression through non-Samd TGF- $\beta$ 1 signaling. *Virus Research.* 2017;235:58-66.
35. Li SW, Wang CY, Jou YJ, Yang TC, Huang SH, Wan L, Lin YJ, Lin CW. SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF- $\beta$ 1 via ROS/p38 MAPK/STAT3 pathway. *Scientific Reports.* 2016;6:25754.
36. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, Laurent GJ, Davis GE, Chambers RC, Matthay MA, Sheppard D. Ligation of protease-activated receptor 1 enhances  $\alpha(v)\beta$ 6 integrin-dependent TGF- $\beta$  activation and promotes acute lung injury. *J Clin Invest* 2006; 116(6):1606–1614.
37. Pittet JF, Griffiths MJ, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LA, Gotwals PJ, Kotliansky VE, Matthay MA, Sheppard D. TGF-beta is a critical mediator of acute lung injury. *J Clin Invest* 2001; 107:1537–1544
38. Frank JA, Matthay MA. TGF- $\beta$  and lung fluid balance in ARDS. *PNAS* 2014; 111: 885-886
39. Peters DM, Vadasz I, Wujak T et al., TGF- $\beta$  directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. *PNAS* 2013; E374–E383 [www.pnas.org/cgi/doi/10.1073/pnas.1306798111](http://www.pnas.org/cgi/doi/10.1073/pnas.1306798111)
40. Budinger S, Chandel NS, Donnelly HK, Eisenbart J, Oberoi M, Jain M. Active transforming growth factor-b1 activates the procollagen I promoter in patients with acute lung injury. *Intensive Care Med* 2005; 31:121–128. DOI 10.1007/s00134-004-2503-2
41. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair CN, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS. Neutrophil extracellular traps in COVID-19. *JCI Insight.* 2020 Apr 24. pii: 138999. doi: 10.1172/jci.insight.138999. [Epub ahead of print]

42. Bossman M, Ward PA. Protein-based Therapies for Acute Lung Injury: Targeting Neutrophil Extracellular Traps. *Expert Opin Ther Targets*. 2014 June ; 18(6): 703–714. doi:10.1517/14728222.2014.902938.
42. Hu X, Huang X. Alleviation of Inflammatory Response of Pulmonary Fibrosis in Acute Respiratory Distress Syndrome by Puerarin via Transforming Growth Factor (TGF- $\beta$ 1). *Med Sci Monit*, 2019; 25: 6523-6531
43. Lev P, Salim J, Marta R, Mela M, Goette N, Molinas F. Platelets possess functional TGF- $\beta$  receptors and Smad2 protein. *Platelets* 2007. 18. 35-42. DOI: 10.1080/09537100600800743.
44. Fox R, Akmatbekov A, Harbert J, Li G, Brown Q, Vander Heide RS. Pulmonary and cardiac Pathology in COVID -19; the first autopsy series from New Orleans. medRxiv. doi: 10.1101/2020.04.06.2
45. Stafford N, Arnold A, Jebakumar S, Manglam V, Sangwaiya A, Arnold J. Therapeutic strategies for COVID-19: New Insights Into The Value Of Transforming Growth Factor Beta (TGF $\beta$ ) Antagonists Such As Imatinib and other Kinase Inhibitors. *BMJ* 2020; 369 doi: <https://doi.org/10.1136/bmj.m1610> (Published 22 April 2020)
46. Shimbori C, Bellaye PS, Xia J et al: Fibroblast growth factor-1 attenuates TGF-beta1-induced lung fibrosis. *J Pathol*, 2016; 240(2): 197–210
47. Nithiananthan S, Crawford A, Knock JC et al: Physiological fluid flow moderates fibroblast responses to TGF-beta1. *J Cell Biochem*, 2017; 118(4): 878–90
48. Wang L, Liu J, Xie W, Li G, Yao L, Zhang R, Xu B. miR-425 reduction causes aberrant proliferation and collagen synthesis through modulating TGF- $\beta$ /Smad signaling in acute respiratory distress syndrome. *Int J Clin Exp Pathol* 2019;12(7):2604-2612
49. Giamarellos-Bourboulis et al., Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure, *Cell Host & Microbe* (2020), doi: 10.1016/j.chom.2020.04.00.
50. <https://themarketherald.com.au/mgc-pharmaceuticals-asxmgc-artemic-combats-covid-19-2020-12-15/>.
51. Lin Y, Wu F, Xie Z, Song X, Zhu Q, Wei J, Tan S, Liang L, Gong B. [Clinical study of Artesunate in the treatment of coronavirus disease 2019]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2020 Apr;32(4):417-420. Chinese. doi: 10.3760/cma.j.cn121430-20200312-00412. <https://pubmed.ncbi.nlm.nih.gov/32527344/>

**Table 1. Patient Demographics and Baseline Characteristics**

<b>Parameter</b>	<b>SOC (N=21)</b>	<b>Artemisinin +SOC (N=39)</b>	<b>Total (N=60)</b>
<b>Age (years)</b>			
Mean ± SD	46.0 ±10.6	41.9±12.4	43.3±11.9
Median (Range)	50.0 (18-59)	44.0 (18-59)	44.5 (18-59)
<b>BMI (kg/m<sup>2</sup>)</b>			
Mean ± SD	25.0 ± 3.5	24.9 ± 3.1	24.9 ± 3.2
Median (Range)	25.5 (19.3-32.4)	24.8 (20.6-35.2)	24.9(19.3-35.2)
<b>Gender</b>			
Male, N (%)	13 (61.9)	25 (64.1)	38 (63.3)
Female, N (%)	8 (38.1)	14 (35.9)	22 (36.7)
<b>Ethnicity</b>			
Hispanic, N (%)	0(0.0)	0(0.0)	0(0.0)
Not Hispanic, N (%)	0(0.0)	0(0.0)	0(0.0)
Asian, N (%)	21 (100)	39 (100)	60 (100)
Others, N (%)	0(0.0)	0(0.0)	0(0.0)
<b>Body temperature (°F)</b>			
Mean ± SD	99.1±0.9	98.8 ± 1.4	99.0±1.1
Median (Range)	98.9(97.4-101.4)	98.8(95.4-102.2)	98.9 (95.4-102.2)
<b>O<sub>2</sub>-saturation in room air (%)</b>			
Mean ± SD	97±1	96±2	97±1
Median (Range)	98 (94-99)	97 (92-99)	97 (92-99)
<b>Score, WHO Clinical Progression Scale</b>			
1. Asymptomatic	0 (0.0)	0 (0.0)	0 (0.0)
2. Symptomatic, Independent	4(19.0)	8(20.5)	12(20.0)
3. Symptomatic, Assistance needed	7(33.3)	13(33.3)	20(33.3)
4. Hospitalized, No oxygen therapy	10(47.6)	18(46.2)	28(46.7)
<b>COVID-19 Confirmed by Positive RT-PCR Test</b>			
Yes, N(%)	21 (100)	39 (100)	60 (100)
No, N(%)	0 (0.0)	0 (0.0)	0 (0.0)

**Table 2. Adverse Events Reported for All Patients Treated with ARTIVeda on the ARTI-19 Study**

System Organ Class (SOC)/ Preferred Term	SOC (N = 21)					ARTIVeda + SOC (N = 39)				
	Unrelated N (%)	Related N (%)	Grade 1 N (%)	Grade 2 N (%)	Grade ≥3 N (%)	Unrelated N (%)	Related N (%)	Grade 1 N (%)	Grade 2 N (%)	Grade ≥3 N (%)
<b>Adverse Events (AE)</b>	6 (28.6)	1 (4.8)	7 (33.3)	0 (0)	0 (0)	7 (17.9)	2 (5.1)	9 (23.1)	0 (0)	0 (0)
<b>Skin and subcutaneous tissue disorders</b>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.6)	1 (2.6)	0 (0)	0 (0)
Rash	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.6)	1 (2.6)	0 (0)	0 (0)
<b>Cardiac Disorders</b>	2 (9.5)	0 (0)	2 (9.5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Tachycardia	2 (9.5)	0 (0)	2 (9.5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Gastrointestinal disorders</b>	0 (0)	1 (4.8)	1 (4.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Abdominal pain	0 (0)	1 (4.8)	1 (4.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>General disorders</b>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (7.7)	0 (0)	3 (7.7)	0 (0)	0 (0)
Pyrexia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (5.1)	0 (0)	2 (5.1)	0 (0)	0 (0)
Asthenia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	1 (2.6)	0 (0)	0 (0)
<b>Investigations</b>	6 (28.6)	0 (0)	6 (28.6)	0 (0)	0 (0)	4 (10.2)	0 (0)	4 (10.2)	0 (0)	0 (0)
Blood pressure increased	2 (9.5)	0 (0)	2 (9.5)	0 (0)	0 (0)	2 (5.1)	0 (0)	2 (5.1)	0 (0)	0 (0)
Heart rate increased	4 (19.1)	0 (0)	4 (19.1)	0 (0)	0 (0)	2 (5.1)	0 (0)	2 (5.1)	0 (0)	0 (0)
<b>Nervous system disorders</b>	1 (4.8)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)	1 (2.6)	1 (2.6)	0 (0)	0 (0)
Vertigo	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.6)	1 (2.6)	0 (0)	0 (0)
Headache	1 (4.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Respiratory disorders</b>	1 (4.8)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Dyspnea	1 (4.8)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Subjects reporting individual adverse events may not add up to the number of subjects within a System Organ Classification (SOC) because a subject may have reported more than one adverse event within an SOC term. For subjects reporting an adverse event with more than one severity assessment under the same MedDRA preferred term (PT), the highest severity is reported. System Organ Class (SOC) and preferred terms within each SOC were sorted alphabetically. The following COVID-19-related presenting signs and symptoms were not included as AEs in this table: Diarrhea, loss of taste/smell, cough, sore throat, conjunctivitis. Each of these have resolved in patients receiving ARTIVeda within 5 days.

**Table 3. Safety Laboratory Test Results**

Parameters	Variable/ Statistics	Artemisinin +SOC (N=39)		SOC (N=21)	
		Screening Visit	Day 28	Screening Visit	Day 28
<b>BUN</b> mg/dL	n	39	38	21	18
	Mean	18.40	18.96	19.30	18.34
	SD	12.52	11.71	12.15	10.28
<b>C-Reactive Protein</b> mg/dL	Median	14.00	13.00	14.00	14.00
	n	39	38	21	18
	Mean	8.31	3.15	7.57	3.06
	SD	4.85	1.50	2.67	1.73
	Median	8.10	3.00	7.60	2.65
<b>Hemoglobin</b> g/dL	n	39	38	21	18
	Mean	12.86	12.79	12.61	12.83
	SD	1.64	1.69	1.80	1.82
	Median	13.20	13.00	12.90	13.25
<b>RBC</b> x10 <sup>6</sup> /μL	n	39	38	21	18
	Mean	4.10	4.25	4.06	4.23
	SD	0.45	0.54	0.62	0.58
	Median	4.10	4.30	4.10	4.27
<b>WBC</b> per μL	n	39	38	21	18
	Mean	6184.65	5771.05	7060.81	6603.16
	SD	3401.96	3479.11	3971.63	3410.43
	Median	6500.00	7025.00	6700.00	7500.00
<b>% Lymphocytes</b>	n	39	38	21	18
	Mean	26.26	30.18	24.71	29.89
	SD	10.96	4.64	9.58	5.38
	Median	29.00	30.00	27.00	30.00




Parameters	Variable/ Statistics	Artemisinin +SOC (N=39)		SOC (N=21)	
		Screening Visit	Day 28	Screening Visit	Day 28
<b>% Neutrophils</b>	n	39	38	21	18
	Mean	67.92	63.24	68.81	64.44
	SD	11.94	4.85	10.72	6.34
	Median	64.00	64.00	64.00	64.00
<b>SGOT (AST)</b> U/L	n	39	38	21	18
	Mean	35.77	32.19	38.02	33.29
	SD	18.81	7.55	19.56	9.07
	Median	31.00	31.00	34.00	35.50
<b>SGPT (ALT)</b> U/L	n	39	38	21	18
	Mean	34.90	33.26	36.64	33.87
	SD	16.91	7.54	21.41	9.20
	Median	35.00	36.00	36.00	38.00
<b>Serum Bilirubin</b> mg/dL	n	39	38	21	18
	Mean	0.86	0.71	1.10	1.10
	SD	0.89	0.21	1.62	1.24
	Median	0.78	0.70	0.80	0.85
<b>Serum Creatinine</b> mg/dL	n	39	38	21	18
	Mean	0.94	1.02	0.99	1.08
	SD	0.25	0.23	0.29	0.23
	Median	0.90	1.02	0.90	1.05

**Table 4. ARTIVeda Accelerates Recovery of Patients with Mild-Moderate COVID-19**

Treatment	Score*	Baseline	EOT Day 5	Day 14	Day 28
<b>Experimental arm, ARTIVeda + SOC N (%)</b>	1	0 (0)	<b>31 (79.5)</b>	39 (100)	39 (100)
	2	8 (20.5)	4 (10.3)	0 (0)	0 (0)
	3	13 (33.3)	4 (10.3)	0 (0)	0 (0)
	4	18 (46.2)	0 (0)	0 (0)	0 (0)
<b>Control arm, SOC N (%)</b>	1	0 (0)	<b>12 (57.1)</b>	21 (100)	21 (100)
	2	4 (19.0)	8 (38.1)	0 (0)	0 (0)
	3	7 (33.3)	1 (4.8)	0 (0.0)	0 (0)
	4	10 (47.6)	0 (0)	0 (0)	0 (0)
P-value; Score 1, Experimental arm vs. Control arm, Fisher's exact test	-	-	<b>P=0.028</b>	-	-

\*Score according to the 10-point WHO clinical progression scale. 1 = asymptomatic; 2=symptomatic, independent; 3=symptomatic requiring assistance; 4=hospitalized, not requiring oxygen therapy.



**Figure 1. ARTIVeda Accelerates Recovery of Patients with Moderate COVID-19.**

Depicted are the recovery curves showing the time to becoming asymptomatic for the SOC alone and SOC plus ARTIVeda groups along with the log-rank P-value for the comparison.